# Imprivata adjudication - 2026-04-27 production ref9

Fresh diff: `scoring/results/imprivata_20260427T200927Z.md`

Ground truth: `data/filings/imprivata/pages.json`

## Summary

Headline verdict counts, using the fresh diff's raw disagreement lines:

| Diff area | ai-right | alex-right | both-defensible | both-wrong | needs-Austin |
|---|---:|---:|---:|---:|---:|
| Deal-level disagreements | 3 | 0 | 0 | 0 | 0 |
| Matched/cardinality divergences | 11 | 0 | 0 | 1 | 0 |
| AI-only rows | 3 | 0 | 0 | 0 | 0 |
| Alex-only rows | 8 | 0 | 0 | 1 | 0 |
| **Total** | **25** | **0** | **0** | **2** | **0** |

Main conclusions:

- AI is right on the deal-level identity/date fields. The filing uses `Imprivata, Inc.` and `Thoma Bravo, LLC`, and this proxy does not state the actual closing/effective date.
- AI is right on atomizing the exact-count NDA group and on the range-bid value structure.
- AI is right that the three strategic-party withdrawals are `DropAtInf`, and Sponsor A is better coded as `DropBelowInf`.
- AI is wrong on the final-round announcement date. The filing supports a non-extension `Final Round Ann` on June 24, 2016, not June 12. Alex's June 9 informal-final and June 24 extension rows are also wrong.

## Deal-level disagreements

- `TargetName`: **ai-right**. Filing evidence: page 2 says the stockholder meeting is for `Imprivata, Inc., a Delaware corporation`; page 27 also heads the company description `Imprivata, Inc.` Action implication: **update reference** to filing-verbatim capitalization/punctuation; no rule change.

- `Acquirer`: **ai-right**. Filing evidence: page 2 says Parent and Merger Sub were formed by an affiliate of `Thoma Bravo, LLC ("Thoma Bravo")`; page 8 identifies Thoma Bravo, LLC as the private-equity firm affiliated with Parent, Merger Sub, and the fund. Action implication: **update reference** to filing-verbatim capitalization/punctuation; no rule change.

- `DateEffective`: **ai-right**. Filing evidence: page 62 says the merger "is expected to be completed in the third quarter of 2016" and that the parties "cannot predict the exact timing"; it does not state September 16, 2016 as an actual effective date. Action implication: **update reference** to `null` for this filing; no rule change.

## Matched/cardinality divergences

- Sponsor B June 9 bid, `bid_value_pershare`: **ai-right**. Filing evidence: page 32 says Sponsor B indicated "a range of $17.00 - $18.00 per share." Under the current range rule, `bid_value_lower=17`, `bid_value_upper=18`, and `bid_value_pershare=null`; Alex's `bid_value_pershare=17` duplicates the lower bound. Action implication: **update reference**; no rule change.

- `Bidder Interest` residual bucket: **ai-right**. Filing evidence: page 28 states that in early 2015 and June 2015 Thoma Bravo informally approached the Company and expressed potential interest, with no specific proposals; page 28 also states that in January 2016 Thoma Bravo reiterated interest at an industry conference, again with no specific proposal. Page 29's March 9, 2016 letter is no longer mere interest because it states a $15.00 per-share cash acquisition proposal. Action implication: **update reference** to include the three pre-proposal `Bidder Interest` rows and treat March 9 as `Bidder Sale` plus `Bid`; no rule change.

- `DropAtInf` residual bucket: **ai-right**. Filing evidence: page 31 says one financial sponsor declined interest shortly after executing a confidentiality agreement; page 32 says Strategic 1 was no longer interested and would not submit an indication of interest; page 32 says Strategic 2 was no longer interested; page 33 says Strategic 3 was no longer interested. These are narrated voluntary withdrawals at the informal stage, not one Sponsor A `DropAtInf` bucket. Action implication: **update reference**; no rule change.

- Barclays `IB` date: **ai-right**. Filing evidence: page 29 says the Board/advisory committee discussed and authorized inquiry into Barclays on March 10, March 14, and March 24, but that is not Barclays acting as advisor. Page 30 says on April 15, 2016 the Board engaged Barclays subject to an engagement letter and Barclays joined the meeting to discuss valuation and strategic alternatives; page 30 then says the Company countersigned the engagement letter on April 19. The first narrated Barclays advisory action is April 15. Action implication: **update reference**; no rule change.

- NDA date mismatches for Strategic 1, Strategic 2, Strategic 3, Sponsor A, and Sponsor B: **ai-right**. Filing evidence: page 31 gives one range: "During the period from May 6 through June 9, 2016" Barclays contacted parties and three strategic parties plus four financial sponsors executed confidentiality agreements, including Thoma Bravo on May 10. Only Thoma Bravo has an exact NDA date; the five named non-Thoma parties in the diff use the range date, whose midpoint is May 23, 2016. Action implication: **update reference** to the range-collapsed date plus rough phrase/flag; no rule change.

- `Final Round Ann` date, AI June 12 vs Alex June 9: **both-wrong**. Filing evidence: page 33 says that on June 12 the Board authorized Barclays to advance Sponsor A, Sponsor B, and Thoma Bravo to the second phase and encourage higher prices. But page 35 is the clean final-round announcement: on June 24 the Chairperson approved setting a July 8 final bid deadline, and later that day Barclays sent final bid process letters to Sponsor B and Thoma Bravo requesting marked merger-agreement drafts by July 7 and final bids by July 8. June 9 is the initial preliminary non-binding indication date, not a final-round announcement; June 12 is a narrowing/second-phase authorization that still included Sponsor A, which never received the final bid process letter. Correct row should be `Final Round Ann` dated 2016-06-24, not an extension. Action implication: **update extraction prompt/rulebook** only if this recurs; the rulebook already points to process letters as `Final Round Ann`. Also **update reference** to remove the June 9 informal-final framing and June 24 extension framing.

- `Final Round` date, AI July 8 vs Alex June 24: **ai-right**. Filing evidence: page 35 sets the final bid deadline at July 8; page 36 says that on July 8, the date by which Sponsor B and Thoma Bravo had been invited to submit final bids, only Thoma Bravo submitted a bid. June 24 is the process-letter/announcement date, not the final-round bid date. Action implication: **update reference**; no rule change.

- `Executed` date, AI July 13 vs Alex July 9: **ai-right**. Filing evidence: page 37 says July 9 was a revised non-binding proposal and a desire to execute before market open on July 11. Page 39 says that on July 13, before the stock market opened, the parties finalized and executed the merger agreement and announced execution. Action implication: **update reference**; no rule change.

## AI-only rows

- `Target Sale` on May 5, 2016: **ai-right**. Filing evidence: page 31 says the Board determined it was in the best interests of the Company and stockholders to take steps to further explore a potential business combination, approved the indicative list, and determined that Barclays should contact each party on the list to gauge interest. Action implication: **update reference** to add the row; no rule change.

- `Financial Sponsor 1` NDA on May 23, 2016: **ai-right**. Filing evidence: page 31 states four financial sponsors executed confidentiality agreements, including Thoma Bravo, and then identifies three financial sponsors as Sponsor A, Sponsor B, and Thoma Bravo. The exact count therefore implies one additional unnamed financial sponsor. AI's placeholder is substantively correct; Alex's "Another financial sponsor" row is the same entity but in legacy wording and with stale date handling. Action implication: **update reference** to current placeholder/date convention; no rule change.

- Sponsor A `DropBelowInf` on June 15, 2016: **ai-right**. Filing evidence: page 33 says Sponsor A told Barclays any second-round bid would not be meaningfully higher than its June 9 price, asked whether it should continue, and Barclays told Sponsor A the Board would not be interested at essentially the same valuation; no further discussions followed. The decisive cutoff is target-side price insufficiency after the informal bid. Action implication: **update reference** from `DropAtInf` to `DropBelowInf`; no rule change.

## Alex-only rows

- `Another financial sponsor` NDA and `Drop`: **ai-right** as to AI's replacement treatment. Filing evidence: page 31 supports an unnamed fourth financial sponsor NDA, and says that one financial sponsor declined interest shortly after executing its confidentiality agreement. AI captures this as `Financial Sponsor 1` NDA plus `DropAtInf`, with the NDA date range collapsed to May 23 and the "shortly after" drop anchored from that inferred NDA date. Alex's generic alias and generic `Drop` are legacy/reference artifacts. Action implication: **update reference**; no rule change.

- Strategic 1 generic `Drop` on June 8: **ai-right** as to AI's `DropAtInf` replacement. Filing evidence: page 32 says Strategic 1 was no longer interested and would not submit an indication of interest. That is a voluntary informal-stage withdrawal. Action implication: **update reference**; no rule change.

- `Final Round Inf Ann` and `Final Round Inf` on June 9: **ai-right** as to AI's omission. Filing evidence: page 32 describes June 9 as the deadline and receipt date for preliminary non-binding indications of interest from Sponsor A, Sponsor B, and Thoma Bravo. It is not a final-round event; the final bid process letters come later on June 24. Action implication: **update reference** to remove these rows; no rule change.

- Strategic 2 generic `Drop` on June 12: **ai-right** as to AI's `DropAtInf` replacement. Filing evidence: page 32 says Strategic 2 was no longer interested in exploring a potential transaction because of other internal corporate priorities. Action implication: **update reference**; no rule change.

- Strategic 3 generic `Drop` on June 14: **ai-right** as to AI's `DropAtInf` replacement. Filing evidence: page 33 says Strategic 3 was no longer interested because of its internal focus on other corporate transactions and a perceived overlap in technologies. Action implication: **update reference**; no rule change.

- `Final Round Ext Ann` on June 24: **both-wrong**. Filing evidence: page 35 supports a final bid process letter on June 24, but not an extension: this was the first final bid deadline setting. AI missed the correct June 24 non-extension `Final Round Ann`; Alex used the wrong extension code. Action implication: **update extraction prompt/rulebook** only if repeated; the correct extraction should have `Final Round Ann` dated June 24. **Update reference** to remove the `Ext` coding.

- `Final Round Ext` on June 24: **ai-right** as to AI's omission. Filing evidence: page 35 is the final bid process letter date; page 36 is the actual July 8 final-bid date. There is no extension event on June 24. Action implication: **update reference** to remove the row; no rule change.

## Rulebook/reference implications

- **Reference updates needed:** yes. The reference should be updated for filing-verbatim deal names, `DateEffective=null`, range-bid structure, Thoma Bravo pre-process interest rows, April 15 Barclays IB date, NDA range midpoint dates, atomized fourth financial sponsor treatment, `DropAtInf` vs generic `Drop` for strategic withdrawals, Sponsor A `DropBelowInf`, July 8 `Final Round`, and July 13 `Executed`.

- **AI extraction update needed:** yes, one substantive correction. Replace the AI's June 12 `Final Round Ann` with a June 24, 2016 `Final Round Ann` sourced to the final bid process letters on page 35. Keep the July 8 `Final Round` row. Do not add June 9 `Final Round Inf*` rows or June 24 `Final Round Ext*` rows.

- **Rulebook change:** not needed based on this deal. The existing rules already support range midpoint dating, range-value fields, exact-count atomization, `DropAtInf`/`DropBelowInf`, and process-letter final-round announcements. If multiple deals show the same June 12 vs June 24 confusion, add a prompt example clarifying that "advance to second phase" should not override a later explicit final bid process letter.

- **Austin decision needed:** none.
